AbbVie Inc. (ABBV) Cash Flow Statement

The wide swings in OCF/NI, from 0.95 in 2026Q2 to 37.76 in 2025Q3, reflect the distorting impact of large non-cash items such as IPR&D impairments and amortization from the Allergan acquisition. While GAAP net income is volatile, operating cash flow remains robust, suggesting that the underlying business generates strong cash earnings. Investors should focus on cash flow rather than net income to assess dividend sustainability.

The upward trajectory in FCF, despite quarterly fluctuations, indicates that Skyrizi and Rinvoq are generating strong cash inflows that offset Humira erosion. The FCF margin improvement from 14.0% in 2024Q2 to 21.8% in 2026Q2 suggests operational leverage and cost discipline. However, the 2025Q1 dip to 10.5% highlights sensitivity to working capital swings, which investors should monitor.

AbbVie's capex intensity is minimal relative to its revenue base, reflecting a business model that relies on external innovation through M&A rather than heavy internal manufacturing investment. This low capital intensity allows for substantial free cash flow generation, which supports the company's high dividend payout and debt reduction efforts. The slight uptick in 2025Q3 to 3.2% of revenue may indicate targeted investments, but overall, capex remains a minor drag on cash flow.

The significant quarterly swings in working capital, particularly the negative changes in 2026Q2 and 2024Q2, suggest that AbbVie's cash flow is sensitive to timing of receivables, payables, and inventory. These swings may reflect rebate accruals and payer dynamics, which are common in the pharmaceutical industry. While they do not indicate a structural deterioration, they create volatility in reported FCF, and investors should adjust for these to assess underlying cash generation.

AbbVie's capital deployment is heavily skewed toward returning cash to shareholders via dividends, which have been consistently around $2.8-3.1B per quarter, and funding strategic acquisitions like ImmunoGen and Cerevel. The minimal buyback activity suggests management prioritizes dividend growth and M&A over share repurchases. This strategy aligns with the need to replace Humira revenue, but the high acquisition spend increases leverage and integration risk, warranting close monitoring.

The substantial gap between cumulative OCF and net income underscores the magnitude of non-cash charges, primarily amortization and impairments, which depress GAAP earnings but do not affect cash generation. This divergence indicates that AbbVie's true cash-earning power is significantly higher than reported net income, supporting its ability to sustain and grow dividends. However, the reliance on acquisitions to drive growth means that future cash flows may be impacted by integration costs and potential impairments.